Actualités UCB (PK) - UCBJY | Actions OTCMarkets

UCB and IBM Collaborate to Personalize Care for Epilepsy Patients

UCB and IBM Collaborate to Personalize Care for Epilepsy Patients - Project Will Use Big Data and Analytics to Address Pressing Public Health...

Don't Get Sacked by Parkinson's - Know the Full Range of Symptoms

Don't Get Sacked by Parkinson's - Know the Full Range of Symptoms Football Legend Forrest Gregg Tackles Parkinson's Disease PR...

UCB and Emory partner to address pressing public health issues for people living with epilepsy

UCB and Emory partner to address pressing public health issues for people living with epilepsy - Researchers will study factors influencing...

VIMPAT® (lacosamide) generates positive results in U.S. Phase 3 monotherapy study

VIMPAT® (lacosamide) generates positive results in U.S. Phase 3 monotherapy study -- Top-line results demonstrate that the conversion to...

New Efforts Underway to Improve Care for Veterans with Epilepsy

New Efforts Underway to Improve Care for Veterans with Epilepsy /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial";...

UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community

UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community /* Style...

UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT® (lac...

UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT® (lacosamide) /* Style...

UCB Harnesses the Voices of the Crohn's Disease Community during Crohn's and Colitis Awareness Week

UCB Harnesses the Voices of the Crohn's Disease Community during Crohn's and Colitis Awareness Week /* Style Definitions...

UCB Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of the American Epilepsy Society

UCB Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of the American Epilepsy Society /* Style Definitions...

The Michael J. Fox Foundation Launches Innovative "Tell Us Your Story" Facebook Campaign To Raise Funds And Awareness For Par...

The Michael J. Fox Foundation Launches Innovative "Tell Us Your Story" Facebook Campaign To Raise Funds And Awareness For...

RAPID™-PsA study showed that certolizumab pegol improved signs and symptoms of psoriatic arthritis in patients with and wit...

RAPID™-PsA study showed that certolizumab pegol improved signs and symptoms of psoriatic arthritis in patients with and without prior anti-TNF...

UCB Announces Data on Cimzia® (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American Col...

UCB Announces Data on Cimzia® (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American College of...

RAPID™-axSpA study showed certolizumab pegol reduced signs and symptoms of axial spondyloarthritis

RAPID™-axSpA study showed certolizumab pegol reduced signs and symptoms of axial spondyloarthritis /* Style Definitions...

New Data From UCB's Immunology Portfolio Highlighted at 2012 American College of Rheumatology Meeting

New Data From UCB's Immunology Portfolio Highlighted at 2012 American College of Rheumatology Meeting /* Style Definitions...

UCB Proudly Reinforces Ongoing Dedication to Patients and Physicians at American College of Gastroenterology 2012 Annual Scie...

UCB Proudly Reinforces Ongoing Dedication to Patients and Physicians at American College of Gastroenterology 2012 Annual Scientific Meeting /...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB (PK) (UCBJY)

Outils de qualité professionnelle, pour des investisseurs individuels.

UCBJY Actualités

UCB and IBM Collaborate to Personalize Care for Epilepsy Patients

Don't Get Sacked by Parkinson's - Know the Full Range of Symptoms

UCB and Emory partner to address pressing public health issues for people living with epilepsy

VIMPAT® (lacosamide) generates positive results in U.S. Phase 3 monotherapy study

New Efforts Underway to Improve Care for Veterans with Epilepsy

UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community

UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT® (lac...

UCB Harnesses the Voices of the Crohn's Disease Community during Crohn's and Colitis Awareness Week

UCB Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of the American Epilepsy Society

The Michael J. Fox Foundation Launches Innovative "Tell Us Your Story" Facebook Campaign To Raise Funds And Awareness For Par...

RAPID™-PsA study showed that certolizumab pegol improved signs and symptoms of psoriatic arthritis in patients with and wit...

UCB Announces Data on Cimzia® (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American Col...

RAPID™-axSpA study showed certolizumab pegol reduced signs and symptoms of axial spondyloarthritis

New Data From UCB's Immunology Portfolio Highlighted at 2012 American College of Rheumatology Meeting

UCB Proudly Reinforces Ongoing Dedication to Patients and Physicians at American College of Gastroenterology 2012 Annual Scie...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB (PK) (UCBJY) Actualités

UCB (PK) (UCBJY)

Outils de qualité professionnelle, pour des investisseurs individuels.

UCBJY Actualités

UCB and IBM Collaborate to Personalize Care for Epilepsy Patients

Don't Get Sacked by Parkinson's - Know the Full Range of Symptoms

UCB and Emory partner to address pressing public health issues for people living with epilepsy

VIMPAT® (lacosamide) generates positive results in U.S. Phase 3 monotherapy study

New Efforts Underway to Improve Care for Veterans with Epilepsy

UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community

UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT® (lac...

UCB Harnesses the Voices of the Crohn's Disease Community during Crohn's and Colitis Awareness Week

UCB Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of the American Epilepsy Society

The Michael J. Fox Foundation Launches Innovative "Tell Us Your Story" Facebook Campaign To Raise Funds And Awareness For Par...

RAPID™-PsA study showed that certolizumab pegol improved signs and symptoms of psoriatic arthritis in patients with and wit...

UCB Announces Data on Cimzia® (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American Col...

RAPID™-axSpA study showed certolizumab pegol reduced signs and symptoms of axial spondyloarthritis

New Data From UCB's Immunology Portfolio Highlighted at 2012 American College of Rheumatology Meeting

UCB Proudly Reinforces Ongoing Dedication to Patients and Physicians at American College of Gastroenterology 2012 Annual Scie...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités